

Index

- ABO antigens, 183
- Action potential
 - cardiomyocytes derived from stem cells, 214
 - measurement with patch clamp electrophysiology, 205
- Acute myeloid leukemia (AML), 241, 250
- Adult stem cell
 - intestinal stem cells
 - colon cancer origins, 246–256
 - discovery, 243–246
 - multipotency and unipotency, 50, 88–100
 - origins, 104
 - prospects for study, 287–288
 - reprogramming, 47
 - therapeutic stem cell transplantation, 135
- Aging, telomere shortening, 51
- Allogenic donor, 187
- ALS, *see* Amyotrophic lateral sclerosis
- Alzheimer's disease, 142
- AML, *see* Acute myeloid leukemia
- Amyotrophic lateral sclerosis (ALS), 225, 290
- Animal models, replacement with stem cell models, 289
- APC, 254
- Armstrong, Lance, 62–63
- Bacteria, mitochondria similarities, 26
- Barnard, Christian, 135
- Blastema, 103
- Blastocyst, 39, 60, 117
- Blastomere, 38, 61
- Blood stem cell, 248
- Bone marrow
 - multipotent cells, 104–105
 - transplantation, 172–173
- Bongso, Arif, 75
- Brachet, Albert, 60
- Bucardo, cloning, 122–123
- California, stem cell initiatives, 193
- California Institute for Regenerative Medicine (CIRM), 267–271
- Campbell, Keith, 128–132
- Cancer stem cell
 - acute myeloid leukemia, 241, 250
 - cell of origin versus cancer stem cell, 241–242, 249–252
 - colon cancer
 - adenoma development, 246–249, 252, 254–246
 - adult intestinal stem cell discovery, 243–246
 - definition, 238
 - differentiation in therapeutic targeting, 251
 - environment–cell interactions, 241
 - evolution of tumor growth, 240–241
 - killing, 252
 - morphology and histology of cancer, 239
- Capecchi, Mario, 70–71
- Cardiomyocyte, *see* Heart stem cell therapy
- Castillo, Claudia, 142
- Cell
 - discovery, 14
 - intercellular communication, 21–22
 - organelles, 2–3
- Cell culture, 26–28, 66–68
- Cell line, 26, 28, 49, 68
- Chromosome, structure, 6, 8
- CIRM, *see* California Institute for Regenerative Medicine
- Clevers, Hans, 243, 247, 254
- Clinical trial
 - phases, 231
 - subjects, 228
- Cloning, *see* Somatic cell nuclear transfer; Therapeutic cloning
- Colon cancer, *see* Cancer stem cell
- Commercial stem cell therapy, *see also* Stem cell tourism
 - advertising, 233
 - International Society for Stem Cell Research perspective, 234–235
 - levels of evidence in treatment, 227–233
 - patient questions, 228–229

- Confocal laser scanning microscope,
204–205
- Cornea, regeneration
- CYPs, *see* Cytochrome P450
- Cytochrome P450 (CYPs), drug
evaluation, 262
- Darwin, Charles, 31
- Deafness, stem cell therapy, 267–271
- Diabetes type I, 146, 154, 156
- DMD, *see* Duchenne's muscular
dystrophy
- DNA
methylation, 13
mutation versus variation, 22–23
overview, 2–3
precipitation, 7
structure, 6, 8–11
- DNA fingerprinting, 114
- DNA microarray, 211–212, 221
- Dolly, *see* Somatic cell nuclear transfer
- Dominant mutation, 23–24
- Down syndrome, 261–263
- Drug discovery
cardiomyocyte differentiation from stem
cells, 212
cell testing, 263–264, 288–289
challenges and opportunities, 260–264
historical perspective, 258, 271
human disease model prospects,
289–290
lead discovery, 260
novel target discovery, 272–274
safety
cardiotoxicity evaluation, 261, 265
hepatotoxicity evaluation, 26
model systems, 266, 271
regulatory agencies, 265
screening prospects, 290–291
- Duchenne's muscular dystrophy (DMD)
dystrophin mutation, 157–158, 184
gene therapy prospects, 156–157
stem cell therapy prospects, 184
- EC cell, *see* Embryonal carcinoma cell
- Ectoderm, 40
- Edwards, Robert, 65, 74
- EG cell, *see* Embryonic germ cell
- Egg, *see* Gamete
- Embryo development
early stages, 36–41
fertilization, 35–36
model systems, 30, 32
overview, 30
- Embryoid body, 61, 174–175, 214–215
- Embryonal carcinoma (EC) cell,
properties, 89, 96–100
- Embryonic germ (EG) cell, 94–95
- Embryonic stem cell
cardiomyocyte differentiation, *see* Heart
stem cell therapy
cell lines, 55, 74–76
development, 47–48
human cells
culture, 79
ethics in regenerative medicine,
167–169
European Human Embryonic Stem
Cell Registry, 98
history of study, 74–78
legislation, 76, 78
isolation, 48–49
mouse cell culture, 66–68, 73–74, 90–93
therapeutic stem cell transplantation,
161–162
- Epidermolysis bullosa, 151
- Epigenetics
transcription regulation, 12–14
twin differences, 22
- Epigenetics
cell division relationship with
differentiation, 55–57
stem cells, 57
X chromosome imprinting, 51–52
- European Human Embryonic Stem Cell
Registry (hESCReg), 98, 153
- Evans, Martin, 64, 66–67, 70–74
- Evidence-based medicine, 227–229
- Extracellular matrix, 171
- FGF, *see* Fibroblast growth factor
- Fibroblast growth factor (FGF), 93
- Fire, Andrew, 25
- Fleming, Alexander, 25
- Flow cytometry, 166, 209, 221, 250
- Fluorescence microscopy, 202–204
- Gamete, 32, 35, 41
- Gardner, Richard, 65
- Gaur, cloning, 121–122
- Gehrig, Lou, 225
- Gel electrophoresis, 211
- Gene, properties, 8–9
- Gene targeting, 263

- Gene therapy
 applications, 190–191
 epidermolysis bullosa, 152
 safety, 185
 stem cell therapy combination, 156–157
- Genetic code, 15
- Genetic predisposition, DNA mutation
 versus variation, 22–23
- Germ cell tumor, 42–43
- Germline stem (GS) cell, 95–96
- Gey, George, 17–18
- GFP, *see* Green fluorescent protein
- Graft-versus-host disease, 172, 186–187
- Graham, Christopher, 74
- Granulocyte–macrophage colony-stimulating factor (GM-CSF), 172
- Green fluorescent protein (GFP)
 chimeric cell detection, 192
 intestinal stem cell discovery, 243–246
- GS cell, *see* Germline stem cell
- Gurdon, John, 110, 128
- Heape, Walter, 60
- Hawthorne, Lou, 117–118
- Harvard Stem Cell Institute
- Heart stem cell therapy
 action potential measurement, 205–208
 cardiomyocyte differentiation from stem cells
 analysis of cells, 220
 culture studies, 220
 drug testing, 216
 efficiency, 214–217
 overview, 207
 congenital defect treatment, 208
 delivery, 218–219
 embryonic stem cell transplantation
 experiments in mice, 199–202
 heart failure clinical trials, 216–217
 myocardial infarction treatment criteria, 202, 205
 myocardium tissue engineering, 217, 216
 progenitor cells for repair, 220–221
 timing, 217–218
- Heart valve, tissue engineering, 177
- HeLa cell, 17–19
- Hematopoietic stem cell, 172
- hESCreg, *see* European Human Embryonic Stem Cell Registry
- HLA, *see* Human leukocyte antigen
- Hollander, Anthony, 144–146
- Hooke, Robert, 20–21
- Hubrecht, Ambrosius, 30–31
- Human leukocyte antigen (HLA)
 classes, 139, 183
 complex, 139–141, 189
 donor matching, 172–173, 187, 189, 287
- Hurler's disease, stem cell
 transplantation, 182
- Hwang, Woo-Suk, 113–114, 124–126
- Immune response
 graft-versus-host disease, 172, 186–187
 transplanted cells, 135–136, 178, 183, 186–188
- Immunofluorescence microscopy, 210
- Imprinting, 52–53
- Induced pluripotent stem (iPS) cell
 cardiomyocyte differentiation, *see* Heart stem cell therapy
 diabetes treatment prospects, 156
 historical perspective, 83–85
 pluripotency genes, 97
 prospects for study, 287
 therapeutic stem cell transplantation, 160, 164
- Inner cell mass, 39, 48
- Intellectual property (IP)
 companies and alliances, 276–278
 ethical issues, 283–284
 Europe versus United States patent law, 280–283
 privacy and ownership, 284
 Wisconsin Alumni Research Foundation, 279–280
- International Society for Stem Cell Research (ISSCR), 228, 234–235
- International Stem Cell Initiative (ISCI), 79
- Interspecies somatic cell nuclear transfer (iSCNT), 120
- In vitro* fertilization (IVF), 74–75, 167
- IP, *see* Intellectual property
- iPS cell, *see* Induced pluripotent stem cell
- ISCI, *see* International Stem Cell Initiative
- iSCNT, *see* Interspecies somatic cell nuclear transfer
- ISSCR, *see* International Society for Stem Cell Research
- IVF, *see* *In vitro* fertilization
- Jaenish, Rudolph, 68

- Karyotype, 8
Kaufman, Matt, 66
Klein, Bob, 192
Kniest, Joke, 226–227
Knockout mouse, 71
- Lacks, Henrietta, 16–19
Lee, Byeong-Chun, 118
Leukemia inhibitory factor (LIF), 67, 93
LGR5, intestinal stem cell discovery, 243–246
LIF, *see* Leukemia inhibitory factor
- Macular degeneration, 150, 152, 188
Major histocompatibility complex (MHC), 139
Martin, Gail, 64, 66
Mass spectrometry, protein analysis, 211
MEF, *see* Mouse embryonic fibroblast
Mello, Craig, 25
Melton, Douglas, 78, 193
Mesoderm, 41
Messenger RNA (mRNA)
 generation, 19, 23
 protein synthesis, 19
 regulation
 epigenetics, 12–14
 RNA interference, 14–15
 transcription factors, 12–13
Metastasis, 251
MHC, *see* Major histocompatibility complex
Micro-RNA (miRNA), 15, 25
Microscopy
 fluorescence microscopy, 202–204
 historical perspective, 4–6
 immunofluorescence microscopy, 210
Miller, Carol, 83
Mintz, Beatrice, 69
miRNA, *see* Micro-RNA
Missyplcity, 117–118
Mitochondria, bacteria similarities, 26
Mouse embryonic fibroblast (MEF), 91–93
mRNA, *see* Messenger RNA
Multipotency
 adult stem cells, 50, 101
 bone marrow cells, 104–105
 definition, 46
 umbilical cord blood cells, 105–107
Multiple sclerosis, 150
Myocardial infarction
 cardiomyocyte therapy from stem cells, *see* Heart stem cell therapy
 consequences, 156, 199
Myocardium
 patches, 216
 tissue engineering, 214
- Neher, Erwin, 206
New York Stem Cell Foundation
- Oligodendrocyte, 80
Ornithine transcarbamylase (OTC), gene therapy for deficiency, 190
OTC, *see* Ornithine transcarbamylase
- Parkinson's disease, 147, 158, 164–165
Patch clamp electrophysiology, action potential measurement, 205–207
Patent, *see* Intellectual property
Pellagrini, Graziella, 154
Personalized medicine, prospects, 290–291
Pets, cloning, 117–119
Planaria, regenerative capacity, 53–54
Pluripotency
 definition, 41, 46
 embryonic stem cell, 47–49
 induced pluripotent stem cell genes, 99
Privacy, donors and ownership rights, 284
Progenitor cell, 47
Protein
 mass spectrometry analysis, 198, 211
 synthesis, 18, 22
- QT prolongation, cardiac drug safety evaluation, 261
- Recessive mutation, 23–24
Regenerative medicine
 applications
 cell loss characteristics in disease, 145–146
 diabetes type I, 146, 156
 inherited versus acquired diseases, 142, 154, 156
 macular degeneration, 150, 151
 multiple sclerosis, 150
 spinal cord injury, 148–151
 cornea, 155
 skin, 148–149

- therapeutic stem cell transplantation
 cell number requirements, 140
 current status, 184, 190
 definition, 179
 ethics, 167–167
 gene therapy combination, 156–157
 Hurler's disease, 182
 immune rejection, 178, 183, 186–189
 immune response, 137–140
 risks, 165–167
 sites of transplantation, 157, 186, 192
 types of cells
 adult stem cells, 159–160
 embryonic stem cells, 162–163
 induced pluripotent stem cells,
 156, 162
 selection factors, 140
 tissue engineering, *see* Tissue engineering
- Retinal pigment epithelium (RPE), 80–81
- Ribosome, 14, 19
- RNA interference
 discovery, 25
 target-based drug discovery, 272–274
 transcription regulation, 13, 19–20
- RPE, *see* Retinal pigment epithelium
- Ruddle, Frank, 83
- Sakmann, Bert, 206
- Salamander, regenerative capacity,
 102–103
- Scadden, David, 193
- SCID, *see* Severe combined
 immunodeficiency
- SCNT, *see* Somatic cell nuclear transfer
- Serendipity, 25
- Severe combined immunodeficiency
 (SCID), gene therapy, 190
- Skin
 artificial, 147–148
 gene therapy, 151–152
- Smithies, Oliver, 67, 70–71
- Solomon, Susan, 193, 195
- Somatic cell nuclear transfer (SCNT)
 challenges, 120, 127
 Dolly, 112–113, 117, 127, 128, 130
 domestic livestock cloning, 126
 extinct animal cloning, 122–123
 historical perspective, 110, 112–117
 Hwang fraud, 113–114, 124–126
 interspecies somatic cell nuclear transfer,
 120
 legislation, 124
 pet cloning, 117–119
 principles, 110–111
 prospects, 113
- Sperling, John, 117–118
- Sperm, *see* Gamete
- Spermatogonial stem cell, 95–97
- Spinal cord injury, 80, 149–150
- Stargardt's macular dystrophy, 188
- Stem cell
 epigenetics, 57
 history of study, 60–62, 64–66, 86
 mobilization, 172
- Stem cell therapy, *see also* Regenerative
 medicine
 embryonic stem cell limitations, 79–80
 potential applications, 80, 83
 United States regulatory environment,
 81
- Stem cell tourism, *see also* Commercial
 stem cell therapy
 advertising, 233
 case study, 228, 231
 International Society for Stem Cell
 Research perspective, 234–235
 levels of evidence in treatment,
 227–233
 overview, 224–225, 227
 patient questions, 228–229
 safety, 230–231
- Stem cell, *see also specific cells*
 definition, 46
 key properties, 46, 57
- Steptoe, Patrick, 74
- Stevens, Leroy, 64
- Suicide gene, 166
- Tada, Takashi, 83
- Tarkowsky, Krzysztof, 65
- T-cell, types, 138
- Telomere shortening
 aging, 51
 cloned animals, 128
- Teratocarcinoma, 42, 62, 64–65
- Teratoma, 42–43, 64
- Therapeutic cloning
 definition, 110
 ethics, 169
 limitations, 116
- Therapeutic stem cell transplantation, *see*
 Regenerative medicine; Stem
 cell therapy
- Thomson, James, 76–78, 208

- Tissue engineering, *see also* Regenerative medicine
 applications, 175–178
 historical perspective, 145
 myocardium
 patches, 216
 tissue engineering, 214
 rationale, 141
 scaffolds, 171, 176
- Totipotency
 definition, 38
 embryonic stem cell, 47–49
- Tourism, *see* Stem cell tourism
- Transcription regulation
 epigenetics, 12–14
 RNA interference, 14–15
 transcription factors, 10, 12–13
- Transgenic mouse, 69, 243
- Trophectoderm, 39, 48
- Trounson, Alan, 269
- Twin paradox, 179–182
- Umbilical cord blood
 banking, 106–107
- Hurler’s disease treatment, 182
- multipotent cells, 105–106
 therapeutic potential, 185, 189
- Unipotency, adult stem cells, 50
- Van Leeuwenhoek, Antoni, 4–6
- WARF, *see* Wisconsin Alumni Research Foundation
- Watson, James, 10
- Weinberg, Robert, 251
- Wilmot, Ian, 128, 130–131
- Wisconsin Alumni Research Foundation (WARF), 279–280
- Wnt, 255
- Woolly mammoth, cloning prospects, 123–124
- X chromosome, imprinting, 51–52
- Yamanaka, Shinya, 83–85
- Zona pellucida, 36
- Zygote, 36–37